

ASX Announcement

28 January 2022

Leading US strategic healthcare executive, Scott Bruder MD, PhD appointed as Advisor to the Board

Highlights

- Renowned physician-scientist executive in the orthobiologics industry, Scott Bruder joins Regeneus as Board Advisor, effective 1 February
- Scott brings 30+ years leadership experience taking clinical regenerative medicine and orthopedic products through to commercial success
- The Founder and CEO of Bruder Consulting & Venture Group, Scott has also held previous senior executive roles at Stryker Corporation, Johnson & Johnson, and Becton, Dickinson & Company

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, is delighted to announce the appointment of Scott Bruder, MD, PhD as a Board Advisor to the Company effective 1 February 2022.

Dr. Bruder is a highly experienced physician-scientist executive in the orthobiologics industry and is currently Founder and CEO of Bruder Consulting & Venture Group, a leading US based consultancy providing strategic expertise in technology, product and market development, clinical and regulatory affairs, reimbursement and health economics, and commercialization strategy for regenerative medicine companies.

Dr. Bruder has also previously served as Chief Medical & Scientific Officer at Stryker Corporation, Chief Science & Technology Officer at Becton, Dickinson & Company, Worldwide Vice President at Johnson & Johnson Regenerative Therapeutics and Johnson & Johnson DePuy Biologics, and Director, Bone & Soft Tissue Regeneration at Osiris Therapeutics.

Regeneus' CEO Karolis Rosickas commented "Scott is one of very few individuals globally to have a unique deep domain expertise, credibility, and network both in regenerative medicine and orthopedics – intersecting fields which are highly relevant to Regeneus and our growth strategy."

"As we continue to develop both our proprietary stem cell technology platform Progenza™ for knee osteoarthritis and Sygenus for pain management and dermatological conditions, Regeneus is focused on working with a strategic partner for the US market to accelerate growth. We are pleased to welcome Scott as a Board Advisor and look forward to working with him."

"I'm delighted to engage Karolis and the Regeneus Board as they navigate the US development and commercialization landscape using their proprietary technologies", said Dr. Bruder. "The company's Medicinal Signaling Cell (MSC) and Secretome platforms have the potential to deliver extraordinary clinical benefit to patients in need around the world."

In 2021 Regeneus executed a US market access engagement with Bruder Consulting & Venture Group, and have since expanded this relationship to encompass their leadership in representing Regeneus in strategic partnering discussions for Progenza™ in knee osteoarthritis in the US.

As the Company continues to explore a US strategic partnership to expedite its clinical development, Scott's appointment as Board Advisor well positions the Company to deliver this in 2022.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

Hannah Howlett, WE Communications
T: 04 5064 8064
E: hhowlett@we-worldwide.com